Queensland COVID-19 research

This page of Queensland’s research related to the COVID-19 pandemic is compiled from information provided by Queensland universities and research institutes.

While many of our researchers are working on potential vaccines, treatments and other medical interventions, other researchers are applying their expertise to other impacts of the pandemic upon our economy and other aspects of society. The data includes immediate research activity, recent relevant work, proposed research (subject to available funds) and other responses using the resources and expertise of our research organisations.

Listing all of 20 matching responses out of 121 total responses.

  • Researchers develop low-cost ventilator to help countries still fighting COVID-19 using a system to automate the ambu bag June 2020

    A team led by Professor Yongsheng Gao at GU have created the Ventil-8, a device that turns ambu bags, the self-inflating hand pump bag used in resuscitation into automated ventilators. “This replacement ventilator needed to be low-cost and built quickly and relatively easily anywhere in the world. A key design requirement was that all its components have to be available locally and accessible within one day, and in sufficient quantities to create thousands.” Professor Gao said. The team settled on a prototype driven by an easily available car windscreen wiper motor that cost just AUS $600. “The makeshift ventilator meets the doctors’ needs, with adjustable volume and speed or breaths per minute and three different Inspiratory/Expiratory (I/E) ratios” said Dr. Mousa Hadipour, a research fellow at GU's Institute for Integrated and Intelligent Systems.

    #Treatment

    Centre

    Institute for Integrated and Intelligent Systems
    Griffith University

    Contact details
    Professor Yongsheng Gao
    Director
    yongsheng.gao@griffith.edu.au
    +61 7 3735 3652
  • Drug discovery team use super-computer to screen compounds for treatment of COVID-19 April 2020

    The QUT Cancer and Ageing Research Program’s drug discovery team is using a super-computer to screen thousands of FDA-approved therapeutics and millions of drug-like compounds to see if any of them could be effective in treating COVID-19. In parallel, they have the capacity to physically screen 40,000 therapeutics in their TRI-based laboratory.

    #Treatment

    Centre

    Cancer and Ageing Research Program
    Queensland University of Technology

    Contact details
    Professor Derek Richard
    derek.richards@qut.edu.au
    +61 7 3443 7236
    Collaborations
    • Institute of Health and Biomedical Innovation
    • Translational Research Institute
    • PA Research Foundation
  • Placebo-controlled randomized Clinical Trial of Perispinal Etanercept (Enbrel) in Australian patients affected by stroke July 2020

    There is a 37% increase of the incidence of stroke in those infected by COVID-19. The underlying pathology of COVID-19 is systemic inflammation and is closely related to post-stroke pathology. Etanercept (Enbrel) has been used for many years to treat inflammatory diseases such as rheumatoid arthritis. A recent trial led by Associate Professor Stephen Ralph from GU's Menzies Health Institute Queensland showed a significant decrease in post-stroke pain levels and reduced muscle spasticity experienced by people affected by stroke. Subject to funding and approvals this treatment will be trialled in Australian COVID-19 patients affected by stroke.

    #Treatment

    Centre

    https://science.des.qld.gov.au/research/capability-directory/?title=Menzies+Health+Institute+Queensland

    • Griffith University
    • University of Southern Queensland
    Contact details
    Associate Professor Stephen Ralph
    Co-investigator
    s.ralph@griffith.edu.au
    +61 7 5552 8583
    Collaborations
  • Reducing COPD Emergency Department presentations through the implementation of a Nurse Case Management Role. July 2020

    With COVID-19 cases presenting to our Emergency Departments (ED), it is important that we understand how to effectively manage the impact of COVID-19 on COPD (Chronic obstructive pulmonary disease) patients. Based upon the findings of pre-COVID-19 research by USQ's Associate Professor Clint Moloney into the value of Nurse Case Managers in improving outcomes for both COPD patients and EDs, a pilot research project is planned for the Gold Coast University Hospital (GCUH). A Nurse Case Manager, proposed to be based in the GCUH ED, would facilitate avoidable ED and hospital admission for patients with COPD and establish a sub-group of patients affected by COVID-19. This will form part of a larger research initiative focused on the economic and relative patient outcomes stemming from the introduction of a Nurse Case Manager role.

    #Treatment

    Centre

    School of Nursing and Midwifery
    University of Southern Queensland

    Contact details
    Associate Professor Clint Moloney
    Clint.Moloney@usq.edu.au
    +61 7 4631 2931
    Collaborations
  • Use of convalescent plasma in clinical trials for the prevention and treatment of COVID-19 June 2020

    Australian research into the use of convalescent plasma in clinical trials for the prevention and treatment of COVID-19 should be supported according to a leading immunologist from Griffith University’s Institute for Glycomics. Professor Michael Good AO, a member of the National COVID-19 Health and Research Advisory Committee and chair of the working group on convalescent plasma therapy, said the working group’s conclusions included the active support of research into trials of convalescent plasma for treatment and prophylaxis. “Convalescent plasma therapy involves the transfusion of blood plasma collected from patients recovered from COVID-19. As they will have produced antibodies against the disease, the aim is to provide passive immunity in infected patients, as opposed to active immunity in patients that would be induced by a vaccine.” said Professor Good. Convalescent plasma is not a new therapy and has been used and trialled in influenza, SARS-CoV-1 and Ebola infection, as well as in many established diseases such as diphtheria and tetanus.

    #Treatment

    Centre

    Institute for Glycomics
    Griffith University

    Contact details
    Professor Michael Good
    Principal Research Leader
    michael.good@griffith.edu.au
    +61 7 5552 9435
  • Global characterisation of COVID-19 June 2020

    Professor John Fraser is leading a global research study “COVID Critical - Global ICU Data Collection and Analysis to Better Understand and Treat Patients” involving more than 300 health centres across 49 countries. To date, there has been no real data on how best to care for COVID-19 patients in intensive care units, particularly the most vulnerable people. In this project, hospitals around the world will contribute critical care data about patients which will be analysed by Dr. Fraser’s research team at the St Andrew’s War Memorial Hospital (part of Wesley Medical Research) to identify the treatments that work best for different patients in different scenarios.

    #Treatment

    Centre

    COVID-19 Rapid Response Research Centre
    Wesley Medical Research

    Contact details
    Professor John Fraser
    Director of the Intensive Care Unit, St Andrews Memorial Hospital
    +61 7 3834 4225
    Collaborations
    • Co-researcher: Associate Professsor Gianluigi Li Bassi
    • Partner: The Common Good
    • Pro-bono support: Amazon and IBM
  • The Long-term Impact of COVID-19 on survivors June 2020

    Evidence from the 2003 SARS outbreak indicates that COVID-19 could substantially affect the quality of life in survivors . This two-year study, led by Associate Professor Gianluigi Li Bassi, ICU Specialist, St Andrew’s War Memorial Hospital (part of Wesley Medical Research), will investigate the long-term impact of COVID-19 on the millions of people infected with the virus around the world, to understand their future medical care. The work by A/Prof Gianluigi Li Bassi aims to understand the impact of COVID-19 on health outcomes such as renal, pulmonary, liver and neurological dysfunction and general health-related quality of life.

    #Treatment

    Centre

    COVID-19 Rapid Response Research Centre
    Wesley Medical Research

    Contact details
    Associate Professor Gianluigi Li Bassi
    ICU Specialist, St Andrew’s War Memorial Hospital
    Collaborations
    Co-researcher: Professor John Fraser, Director ICU, St Andrews War Memorial Hospital
  • Protecting frontline workers from COVID-19 June 2020

    Prof Bala Venkatesh, Director of the Intensive Care Unit at the Wesley Hospital is leading the “Protecting frontline workers from COVID-19” research project. The project, due for completion in July 2020, sets out to determine whether the safe, low-cost, orally available agent – hydroxychloroquine – will prevent COVID-19 infection in healthcare workers. HCQ has shown promising efficacy in preventing COVID-19 in previous research – but needs to be tested in a large multi-site clinical trial. Every day, front-line healthcare workers come face-to-face with COVID-19; putting their lives at risk in order to save others. In the 2003 SARS pandemic, healthcare workers accounted for 21% of global cases. This trial does not use of hydroxychloroquine for the treatment of COVID-19, it is only being tested with healthy healthcare workers for preventative or prophylactic use.

    #Treatment

    Centre

    COVID-19 Rapid Response Research Centre
    Wesley Medical Research

    Contact details
    Professor Bala Venkatesh
    Director of the Intensive Care Unit at The Wesley Hospital
    balasubramanian.venkatesh@uq.edu.au
    +61 7 3721 1500
    Collaborations
    Partners: The George Institute for Global Health
  • Six COVID-19 drug leads identified April 2020

    A team of international researchers, including some from UQ, has tested over 10,000 approved drugs, drug candidates in clinical trials and other compounds as potential leads for fighting COVID-19. The research involved a program of high-throughput drug screening, both in laboratories and using computer software to predict how different drugs bind to the virus. The main COVID-19 virus enzyme called main protease or Mpro, was targeted as it plays a pivotal role in viral replication and transcription – but as humans don’t carry this enzyme, drugs that target Mpro are likely to have low toxicity for people. Researchers identified six drugs that appear to effectively inhibit the enzyme, with one drug of particular interest. The results of the study have been published in Nature for researchers across the world.

    #Treatment

    Centre

    School of Chemistry and Molecular Biosciences
    The University of Queensland

    Contact details
    Professor Luke Guddat
    luke.guddat@uq.edu.au
    +61 7 3365 3549
    Collaborations
    • Project Leaders: ShanghaiTech University
    • Funders:
    • National Key R&D Programmes of China
    • Project of International Cooperation and Exchanges - National Natural Science Foundation of China
    • Science and Technology Commission of Shanghai Municipality
    • Department of Science and Technology of Guangxi Zhuang Autonomous Region
  • Telehealth and coronavirus: Medicare Benefits Schedule (MBS) activity in Australia May 2020

    In March 2020, additional telehealth item numbers were added to the Australian Medicare Benefits Schedule (MBS) to encourage physical distancing, for those accessing medical, nursing and allied health services during the coronavirus (COVID-19) pandemic. UQ's Centre for Online Health (COH) has analysed the MBS service data and summarised telehealth uptake throughout Australia. This information will be updated on a monthly basis.

    #Treatment

    Centre

    The University of Queensland

    Contact details
    Doctor Centaine Snoswell
    Research Fellow Health Economics
    c.snoswell@uq.edu.au
    +61 7 3176 5314
    Collaborations
    • Co-researchers:
    • Monica Taylor
    • Georgina Hobson
    • A/Prof. Liam Caffery
    • Dr. Emma Thomas
    • Dr. Helen Haydon
    • Prof. Anthony Smith
    • Collaborator: NHMRC Partnership Centre for Health System Sustainability
  • Accelerating technology uptake during a pandemic: enabling and extending delivery of rehabilitation. August 2020

    COVID-19 significantly disrupted the delivery of healthcare, especially in areas that require physical interaction, such as disability and rehabilitation. Although existing technology could enable remote interventions, its widespread adoption is limited. In this Advance Queensland Industry Research Fellowship project led by Dr Camila Shirota from the Griffith University Hopkins Centre, a Technology Assessment and Adoption Framework will be co-designed across multiple stakeholders, to accelerate and facilitate the uptake of remote technology in rehabilitation settings across Queensland.

    #Treatment

    Centre

    The Hopkins Centre, Menzies Health Institute Queensland
    Griffith University

    Contact details
    Dr Camila Shirota
    Research Fellow
    c.shirota@griffith.edu.au
    +617 3735 4342
    Collaborations
    • Spinal Life Australia
    • Metro South Hospital and Health Service
    • Motor Accident Insurance Commission
    • Advanced Robotics for Manufacturing Hub
    • Gold Coast Hospital and Health Service
    • The University of Queensland
  • Advancing a clinical drug targeting the complement system to treat COVID-19. August 2020

    COVID-19 is an infectious and potentially lethal respiratory disease that has altered the way we all live. There is, therefore, an urgent need to identify effective drugs for this disease. This Advance Queensland Industry Research Fellowship project led by Dr. John Lee at UQ School of Biomedical Sciences entails validating and advancing a pre-existing clinical drug that targets our immune system, in the hope of finding an effective therapy for COVID-19 patients.

    #Treatment

    Centre

    School of Biomedical Sciences
    The University of Queensland

    Contact details
    Dr John Lee
    Postdoctoral Research Fellow
    j.lee9@uq.edu.au
    +61 7 336 52384
    Collaborations
    Alsonex Pty Ltd
  • Application of separation technologies for rapid treatment of COVID-19 and related outbreaks. August 2020

    This Advance Queensland Industry Research Fellowship project led by Dr. Craig Bell from UQ's Australian Institute for Bioengineering and Nanotechnology aims to produce a rapid, first-pass treatment for COVID-19 patients, and inoculation protection for front-line health workers. This project will evaluate application of separation membranes to create concentrated antibody-rich hyperimmune sera derived from blood of recovered COVID-19 patients. Without working vaccines, hyperimmune sera are the only viable rapid turnaround treatment for infectious diseases now and in the future.

    #Treatment

    Centre

    Australian Institute for Bioengineering and Nanotechnology
    The University of Queensland

    Contact details
    Dr. Craig Bell
    UQ Amplify Researcher
    c.bell1@uq.edu.au
    +61 7 3346 0322
    Collaborations
    Aegros
  • Artificial Intelligence (AI)-supported real-time assessment of ventilation and blood-flow ratio in lungs. August 2020

    COVID-19 patients have a poor gas exchange in the lungs where the lungs may be easy to ventilate but do not match blood flow. This mismatch of ventilation and blood perfusion (V/Q ratio) affects the delivery of oxygen around the body and the excretion of carbon dioxide. If not treated optimally respiratory-failure may ensue - the main cause of COVID-19-related mortality. This Advance Queensland Industry Research Fellowship project led by Dr Aida Brankovic with UQ's School of Information Technology and Electrical Engineering will develop a bedside AI-supported tool based on electromagnetic technology for real-time assessment of gas exchange. It will dynamically image lung fluid, the amount of blood and gas in the lungs. This will allow repeat bedside scanning that minimises toxic exposures and movement of critical and infectious patients for ventilation/perfusion lung scans.

    #Treatment

    Centre

    School of Information Technology and Electrical Engineering
    The University of Queensland

    Contact details
    Dr. Aida Brankovic
    Postdoctoral Research Fellow
    a.brankovic@uq.edu.au
    +61 7 3365 2697
    Collaborations
    • Co-researcher: Prof. Amin Abbosh
    • Collaborators:
    • EMvison Medical Devices
    • Princess Alexandra Hospital
    • Keysight Technology
  • Impact and implications of COVID-19 on clinical supervision in hospital settings. August 2020

    This Advance Queensland Industry Research Fellowship project led by Dr. Priya Martin at the Darling Downs Hospital and Health Service's Cunningham Centre will investigate the impact of the COVID-19 pandemic on clinical supervision practices of health professionals and students in regional and rural Queensland Health settings. Recommendations and strategies will be developed to negate the impact of this pandemic so that effective clinical supervision practices are maintained at the point of care.

    #Treatment

    Centre

    Cunningham Centre - Darling Downs Hospital and Health Service
    Queensland Health

    Contact details
    Dr. Priya Martin
    Adjunct Fellow - Rural Clinical School
    priya.martin@uq.edu.au
    +61 7 4037 4743
    Collaborations
    • Southern Queensland Rural Health
    • UQ Rural Clinical School
    • University of South Australia
  • MitoKhondrion: Decreasing COVID-19 mortality by increasing the functioning of our cell’s powerhouses. August 2020

    Protecting our most vulnerable from COVID-19 death is a prime medical priority. Kidney disease, often diabetes-caused, can contribute significantly to health complications in COVID-19 patients. Indeed 20-40% of COVID-19 patients in intensive care units suffer kidney failure. This Advance Queensland Industry Research Fellowship project led by Dr. Mitchell Sullivan with Mater Research aims to significantly improve COVID-19 survival rates by protecting kidneys using a novel approach with potentially broad application to coronavirus diseases.

    #Treatment

    Centre

    Mater Research
    The University of Queensland

    Contact details
    Dr. Mitchell Sullivan
    Mater Research Career Track Fellow
    mitchell.sullivan@mater.uq.edu.au
    Collaborations
    Mater Misericordiae Ltd
  • Optimising telehealth to future-proof the delivery of autism related services. August 2020

    This Advance Queensland Industry Research Fellowship project led by A/Prof David Trembath from the Griffith University Hopkins Centre will support Queensland’s lead service provider for individuals with autism and their families as it responds to COVID-19 disruption and builds resilience through the transition to telehealth delivery. The work will identify and extend the most effective models to keep individuals and families supported, minimise staff impacts, and improve access to services for regional and remote Queenslanders.

    #Treatment

    Centre

    The Hopkins Centre, Menzies Health Institute Queensland
    Griffith University

    Contact details
    A/Prof David Trembath
    Deputy Research Director
    d.trembath@griffith.edu.au
    +617 5678 0103
    Collaborations
    Autism Queensland
  • Preventing the respiratory failure causing COVID-19 mortality, potent new drugs targeting hyperinflammation. August 2020

    This Advance Queensland Industry Research Fellowship project led by Dr. Lisa Philp from QUT's Institute of Health and Biomedical Innovation will develop highly potent novel drugs to prevent and cure acute respiratory distress syndrome, the rapid-onset life-threatening respiratory failure that is killing patients with COVID-19 and other respiratory viruses. These drugs will save lives by targeting adipokine receptors responsible for the extreme overreaction of the body’s immune system and hyperactive inflammatory response that underpin rapid patient decline from respiratory failure.

    #Treatment

    Centre

    Institute of Health and Biomedical Innovation
    Queensland University of Technology

    Contact details
    Dr. Lisa Philp
    Postdoctoral Research Fellow
    lisa.philp@qut.edu.au
    +61 7 3443 7283
    Collaborations
    • Allysta Pharmaceuticals, Inc.
    • Arrevus, Inc.
    • Royal Brisbane and Women's Hospital
    • Princess Alexandra Hospital ICU
    • Translational Research Institute
  • QUT and Oxford researchers collaborate on new COVID-19 asthma drug trial July 2020

    QUT mathematician, physician and Australian Research Council Future Fellow, A/Prof. Dan Nicolau, is a lead researcher in the STOIC (STerOids In COVID-19) trial. Along with co-researcher Prof. Mona Bafahdel from University of Oxford, A/Prof. Dan Nicolau had noticed early in the pandemic that people with asthma and the chronic obstructive pulmonary disease (COPD) were under-represented in the numbers of seriously ill COVID-19 patients. The STOIC trial is looking at whether asthma inhalers given to people with early stage COVID-19 can reduce progression of respiratory illness and cut emergency department presentations and hospital admissions. A/Prof. Nicolau and the QUT team will be coordinating trial data analysis, modelling of pathological mechanisms and building COVID-19 maths models to explain and use the clinical trial data to optimise patient treatment, while Prof. Bafahdel will lead the clinical trial with about 500 patients. Some patients will be given the inexpensive, widely-prescribed inhaler medication corticosteroid budesonide that is used to prevent and control asthma symptoms, while others are given a placebo. Budesonide acts to reduce irritation and inflammation of the lungs and airways.

    #Treatment

    Centre

    Science and Engineering Faculty, School of Mathematical Sciences
    Queensland University of Technology

    Contact details
    A/Prof Dan Nicolau
    Future Fellow, Science and Engineering Faculty
    dan.nicolau@qut.edu.au
    +61 7 3138 5238
    Collaborations
    • Co-researchers: Alexander Hasson - QUT Honours student
    • Prof. Mona Bafahdel - University of Oxford
    • A/Prof. Dr Nabil Fadai - University of Nottingham
  • Stopping COVID-19 by targeting the viral replication. August 2020

    This Advance Queensland Industry Research Fellowship project led by Dr. Mark Adams at QUT's Institute of Health and Biomedical Innovation seeks to determine the effectiveness of a novel anti-SARS-CoV-2 (COVID-19 causing virus) candidate named DLSK02. DLSK02 is a first-in-class inhibitor of the SARS-CoV-2 replication complex. If the drug works, it will effectively stop the ability of the virus to replicate and survive.

    #Treatment

    Centre

    Institute of Health and Biomedical Innovation
    Queensland University of Technology

    Contact details
    Dr. Mark Adams
    Strategic Research Fellow
    mn.adams@qut.edu.au
    +61 7 3443 7324
    Collaborations
    CARP Pharmaceuticals

Other Queensland COVID-19 initiatives

Queensland Government
Coronavirus (COVID-19) business assistance finder
Life Sciences Queensland
Life Sciences Queensland joins the data-powered alliance to stop COVID-19

Key Australian COVID-19 initiatives

Australian Academy of Science
COVID-19 Expert Database
Rapid Research Information Forum (RRIF)

Key international COVID-19 initiatives

CORD-19 (COVID-19 Open Research Dataset)
Free database of 130,000 plus COVID-19 open research papers